Meifeng Tu

2.4k total citations
65 papers, 747 citations indexed

About

Meifeng Tu is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Meifeng Tu has authored 65 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pathology and Forensic Medicine, 26 papers in Oncology and 15 papers in Hematology. Recurrent topics in Meifeng Tu's work include Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Meifeng Tu is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Meifeng Tu collaborates with scholars based in China, Ethiopia and United States. Meifeng Tu's co-authors include Ningjing Lin, Lingyan Ping, Zhitao Ying, Wen Zheng, Xiaopei Wang, Yuqin Song, Weiping Liu, Yan Xie, Jun Zhu and Lijuan Deng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Meifeng Tu

61 papers receiving 737 citations

Peers

Countries citing papers authored by Meifeng Tu

Since Specialization

Citations

This map shows the geographic impact of Meifeng Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meifeng Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meifeng Tu more than expected).

Fields of papers citing papers by Meifeng Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meifeng Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meifeng Tu. The network helps show where Meifeng Tu may publish in the future.

Co-authorship network of co-authors of Meifeng Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Meifeng Tu. A scholar is included among the top collaborators of Meifeng Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meifeng Tu. Meifeng Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial 2024 ·BMC Medicine ·Yanfei Liu, Lingyan Ping, Yuqin Song, (unknown), Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, (unknown), Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie	2
2	A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma 2022 ·Chinese Journal of Cancer Research ·Zhitao Ying, Ting He, Shanzhao Jin, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Weiping Liu, Lijuan Deng, Yanping Ding, Xuelian Hu, Bing Bu, Xin‐an Lu, Yuqin Song, Jun Zhu	5
3	Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial 2022 ·Bone Marrow Transplantation ·Zhitao Ying, Yan Xie, Wen Zheng, Weiping Liu, Ningjing Lin, Meifeng Tu, Xiaopei Wang, Lingyan Ping, Lijuan Deng, Chen Zhang, Meng Wu, Feier Feng, Tingting Du, (unknown), Fang Su, Z. J. Guo, James Li, Yuqin Song, Jun Zhu	5
4	Primary mediastinal large B cell lymphoma 2021 ·Thoracic Cancer ·(unknown), Xifeng Dong, Meifeng Tu, Huaquan Wang	8
5	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation 2019 ·Chinese Journal of Cancer Research ·Zhitao Ying, Lan Mi, Nina Zhou, Xuejuan Wang, Zhi Yang, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Jun Zhu	6
6	ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma 2019 ·Cancer Cell International ·Yalu Liu, (unknown), Lijuan Deng, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Ning Ding, Yuqin Song, Jun Zhu	23
7	Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas 2018 ·International Journal of Medical Sciences ·(unknown), Xiaopei Wang, Yan Xie, Weiping Liu, Chen Zhang, Lingyan Ping, Zhitao Ying, Lijuan Deng, Wen Zheng, Ningjing Lin, Meifeng Tu, Yuqin Song, Jun Zhu	11
8	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity 2018 ·BMC Cancer ·Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su, Hanyun Ren, Ningjing Lin, Yan Xie, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu	8
9	NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53 2017 ·Modern Pathology ·Qingqing Cai, Meifeng Tu, Zijun Y. Xu‐Monette, Ruifang Sun, Ganiraju C. Manyam, Xiaolu Xu, Alexandar Tzankov, Eric D. Hsi, Michael Møller, L. Jeffrey Medeiros, Chi Young Ok, Ken H. Young	14
10	Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation 2017 ·Chinese Journal of Cancer Research ·Zhitao Ying, Lan Mi, Xuejuan Wang, (unknown), Zhi Yang, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Jun Zhu	3
11	PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma 2017 ·Chinese Journal of Cancer Research ·Wen Zheng, Hanyun Ren, Xiaoyan Ke, Mei Xue, Yongqing Zhang, Yan Xie, Ningjing Lin, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu	9
12	Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome 2016 ·Annals of Hematology ·Jing Jia, Yuqin Song, Ningjing Lin, Weiping Liu, Lingyan Ping, Wen Zheng, Xiaopei Wang, Yan Xie, Meifeng Tu, Chen Zhang, Zhitao Ying, Lijuan Deng, Ning Ding, Jun Zhu	29
13	DICEレジメンによる97例の再発/難治性非ホジキンリンパ腫患者の治療効果と生存分析【JST・京大機械翻訳】 2016 ·(unknown), Yuqin Song, Wen Zheng, Xiaopei Wang, (unknown), (unknown), Meifeng Tu, (unknown), (unknown), Chen Zhang, (unknown), (unknown)	1
14	Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma 2015 ·Medical Oncology ·Yan Xie, Yuntao Zhang, Wen Zheng, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Lingyan Ping, Zhitao Ying, Chen Zhang, Weiping Liu, Lijuan Deng, Yuqin Song, Jun Zhu	6
15	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis 2015 ·Journal of Hematology & Oncology ·Xin Cao, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, (unknown), Shaoying Li, Muzaffar H. Qazilbash, C. Cameron Yin, Donna Weber, Roberto N. Miranda, Zijun Y. Xu‐Monette, L. Jeffrey Medeiros, Ken H. Young	16
16	[Clinical characteristics and prognosis analysis of patients with LMP-1 positive Hodgkin's lymphoma after EBV infection]. 2014 ·PubMed ·Lingyan Ping, Ning Ding, Yunfei Shi, (unknown), Wen Zheng, (unknown), Xiaopei Wang, Meifeng Tu, Ningjing Lin, Zhitao Ying, Weiping Liu, Lijuan Deng, Zhan Chen, Le Tian, Lixia Feng, Yuqing Song, (unknown)	4
17	The Clinical and Immune Characteristics of Patients with Hepatitis-Associated Aplastic Anemia in China 2014 ·PLoS ONE ·Huaquan Wang, Meifeng Tu, Rong Fu, Yuhong Wu, Hong Liu, Limin Xing, Zonghong Shao	27
18	Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma 2014 ·Cancer Cell International ·(unknown), Jun Zhu, Wen Zheng, Weiping Liu, Zhitao Ying, Yan Xie, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Lingyan Ping, Lijuan Deng, Chen Zhang, Ning Ding, Yuqin Song	5
19	Circulating myeloid dendritic cells are increased in individuals with severe aplastic anemia 2011 ·International Journal of Hematology ·Zonghong Shao, Meifeng Tu, Huaquan Wang, (unknown), Jun Wang, Rong Fu, Hong Liu, Yuhong Wu	35
20	Clinical observation on rituximab combined with chemotherapy in the treatment of diffused large B cell lymphoma. 2009 ·Tumori ·Yan Xie, (unknown), Wen Zheng, Yuntao Zhang, Xiaopei Wang, Yuqin Song, Meifeng Tu	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact